On September 24, 2026, a clinical trial listing was updated to reflect completed status. The trial, registered as NCT07816900 and titled "Efficacy and Safety of Da-Cheng-Qi Decoction in Severe Acute Pancreatitis," involves somatostatin. The listing does not specify a phase, recording it as not applicable.
The trial status is now listed as completed as of the update date. No results, outcomes, or efficacy data were included in this update. The listing confirms only that the study has concluded, without detailing findings or conclusions drawn from it.
Somatostatin remains classified as an unapproved compound for research use. This update pertains solely to the trial's completion status and does not represent a report on safety or benefit. Readers should not interpret trial completion as an indication of results, positive or negative, regarding the treatment studied.
Further details about the trial, including any eventual results, would be expected to appear in future updates to the registry listing. For more background on somatostatin itself, readers can consult the compound overview.